EC Number   |
Application |
Reference |
|---|
    1.16.3.1 | analysis |
enzyme can be used in analytical biochemistry, especially for the construction of enzyme sensors, enzymes immobilized in enzyme-containing membranes coating oxygen sensitive electrodes and serve for a specific amperometric determination of their substrates in biological materials |
438025 |
| 1.16.3.1 | biotechnology |
compartmentalized iron oxide biomineralization by the enzyme yields uniform nanoparticles strictly determined by the sizes of the compartments, allowing customization for highly diverse nanotechnological applications |
-, 746541 |
| 1.16.3.1 | biotechnology |
expression system is developped producing about 2 mg of purified Bacillus sp. strain PL-12 Mn(II) oxidase per liter of Escherichia coli culture in 5 days |
728688 |
| 1.16.3.1 | medicine |
after induction of cerebral ischemia by ligating bilateral common carotid arteries, the expression of ceruloplasmin mRNA in the cortex and hippocampus decreases, and the longer the animals experience ischemia, the lower the expression. Iron concentration correlates negatively with ceruloplasmin expression |
689209 |
| 1.16.3.1 | medicine |
both hypoxia and CuCl2 increase ceruloplasmin mRNA levels in hepatoma cells due to transcriptional induction of enzyme gene promoter |
672774 |
| 1.16.3.1 | medicine |
clinical importance because of its role in iron and copper metabolism and transport |
438011 |
| 1.16.3.1 | medicine |
clinical interest relates to its critical role in the diagnosis of Wilson's disease in serum from patients, marked reduction in serum of patients |
437996, 438006, 438007, 438014, 438027 |
| 1.16.3.1 | medicine |
different forms of normal and pathological ceruloplasmins, increasing ceruloplasmin activity in the blood of schizophrenics |
437996 |
| 1.16.3.1 | medicine |
homogenous ceruloplasmin with ferroxidase activity for the treatment of aplastic anemics, aplastic anemics have low levels of this enzyme, clinical trials have shown effective in 56% of cases |
438016 |
| 1.16.3.1 | medicine |
in fluid from patients with Parkinson's disease, Alzheimer's disease, and Huntington's disease, a significantly decreased ferroxidase activity is found agreeing with findings of iron deposition in these entities, while free copper is found to be increased in cerebrospinal fluid and appears to be a good biomarker of Parkinson's disease. The sum of nitrites and nitrates as end products of nitric oxide are increased in the degenerative diseases Parkinson's disease, Alzheimer's disease, Huntington's disease and lateral amyotrophic sclerosis, and fluorescent lipoperoxidation products in three of them, excepting lateral amyotrophic sclerosis |
689179 |
